<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04073771</url>
  </required_header>
  <id_info>
    <org_study_id>2018ZDSYLL152-P01</org_study_id>
    <secondary_id>18CECACAP1004</secondary_id>
    <nct_id>NCT04073771</nct_id>
  </id_info>
  <brief_title>A Multiple Centre, Cohort Study of New CRRT Membranes oXiris for Patients With Septic Shock</brief_title>
  <official_title>A Multiple Centre, Cohort Study of New Continuous Renal Replacement Therapy (CRRT) Membranes oXiris for Patients With Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southeast University, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Southeast University, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to determine whether Continuous Renal Replacement Therapy
      (CRRT) with oXiris in patients with septic shock would improve clinical outcomes such as the
      sepsis-related organ failure assessment (SOFA) , hemodynamic, mortality compared CRRT with
      conventional membrane.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sepsis is the leading cause of death in ICU, resulting in multi-organ failure in critically
      ill patients. Patients with septic shock combined sepsis-associated Acute kidney injury
      (AKI)have even poorer outcome.

      Endotoxin activity, inflammation and immune dysfunction, have been consider relevant to their
      pathogenesis of sepsis. High levels of Inflammation are associated with worse clinical
      outcomes. However, all studies of anti-inflammation treatment in sepsis patient are failed
      and anti-inflammation treatment of sepsis still remains controversial.

      oXiris is a new filter with adsorptive membrane, which removes endotoxin and inflammatory
      mediator from plasma. But current evidence of oXiris is limited, and only some small sample
      studies have proved that it can improve the haemodynamics and the sepsis-related organ
      failure assessment(SOFA) score.

      Our hypothesis was that oXiris would be associated with better clinical outcomes, such as
      decreased SOFA score, improved survival rate, better hemodynamic, and improved of organ
      function.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 21, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The Sepsis-related Organ Failure Assessment(SOFA) cardiovascular Scores</measure>
    <time_frame>72 hours after Continuous Renal Replacement Therapy initiation</time_frame>
    <description>The Sepsis-related Organ Failure Assessment(SOFA) cardiovascular Scores at 72 hours(Scores Range 0-4, higher values represent a worse outcome)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of Sepsis-related Organ Failure Assessment(SOFA) Score</measure>
    <time_frame>72 hours after Continuous Renal Replacement Therapy initiation</time_frame>
    <description>Changes from baseline to 72 hours in Sepsis-related Organ Failure Assessment(SOFA) Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Norepinephrine dose</measure>
    <time_frame>72 hours after Continuous Renal Replacement Therapy initiation</time_frame>
    <description>Norepinephrine dose at 72 hours after Continuous Renal Replacement Therapy initiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Norepinephrine dose Over Time</measure>
    <time_frame>72 hours after Continuous Renal Replacement Therapy initiation</time_frame>
    <description>Difference of Norepinephrine dose at 72 hours compared with Continuous Renal Replacement Therapy initiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasopressor-free days</measure>
    <time_frame>Day 28</time_frame>
    <description>Vasopressor-free days to day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lactate concentration</measure>
    <time_frame>72 hours after Continuous Renal Replacement Therapy initiation</time_frame>
    <description>Lactate concentration level at 72 hours after Continuous Renal Replacement Therapy initiation initiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>Day 28</time_frame>
    <description>All cause mortality to day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total length of mechanical ventilation</measure>
    <time_frame>Day 28</time_frame>
    <description>Total length of mechanical ventilation to day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total length of Continuous Renal Replacement Therapy</measure>
    <time_frame>Day 28</time_frame>
    <description>Total length of Continuous Renal Replacement Therapy to day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Intensive Care Unit stay</measure>
    <time_frame>Day 28</time_frame>
    <description>Duration of Intensive Care Unit stay to day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Hospital stay</measure>
    <time_frame>Day 28</time_frame>
    <description>Duration of Hospital stay to day 28</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">172</enrollment>
  <condition>Acute Kidney Injury Due to Sepsis (Disorder)</condition>
  <arm_group>
    <arm_group_label>Cohort study</arm_group_label>
    <description>Patients with septic shock undergoing continuous renal replacement therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous renal replacement therapy with oXiris</intervention_name>
    <description>Continuous renal replacement therapy with oXiris in patient with septic shock</description>
    <arm_group_label>Cohort study</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Septic shock patients due to abdominal or pneumonia( Gram-negative bacterial infection or
        suspected GNB infection) treated by CRRT
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;18 Years

          -  Treated by CRRT using oXiris or conventional membrane

          -  SOFA cardiovascular Score ≥ 3

          -  Septic shock due to abdominal or pneumonia( Gram-negative bacterial infection or
             suspected GNB infection)

          -  Written informed consent

        Exclusion Criteria:

          -  Chronic Kidney Disease

          -  Renal replacement therapy (RRT) in the last 30 days

          -  Pregnancy

          -  Immunosuppressive treatment or steroids (prednisone &gt; 0.5 mg/kg/day or equivalent).

          -  Autoimmune disorder.

          -  Transplant receptor.

          -  Inclusion in other ongoing studies within the last 30 days.

          -  Coexisting illness with a high probability of death
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Songqiao Liu, PHD.</last_name>
    <phone>025-83262553</phone>
    <email>liusongqiao@ymail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yi Yang, PHD.</last_name>
    <phone>025-83262553</phone>
    <email>yiyiyang2004@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhongda Hospital, Southeast University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Songqiao Liu, Doctor</last_name>
      <phone>025-83262550</phone>
      <email>liusongqiao@yamil.com</email>
    </contact>
    <contact_backup>
      <last_name>Haibo Qiu, Doctor</last_name>
      <phone>025-83262553</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Department of Nephrology, Sichuan University West ChinaHospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ling Zhang, Doctor</last_name>
      <phone>086-28-85582944</phone>
      <email>zhanglinglzy@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Hoste EAJ, Kellum JA, Selby NM, Zarbock A, Palevsky PM, Bagshaw SM, Goldstein SL, Cerdá J, Chawla LS. Global epidemiology and outcomes of acute kidney injury. Nat Rev Nephrol. 2018 Oct;14(10):607-625. doi: 10.1038/s41581-018-0052-0. Review.</citation>
    <PMID>30135570</PMID>
  </reference>
  <reference>
    <citation>Shum HP, Chan KC, Tam CW, Yan WW, Chan TM. Impact of renal replacement therapy on survival in patients with KDIGO stage 3 acute kidney injury: A propensity score matched analysis. Nephrology (Carlton). 2018 Dec;23(12):1081-1089. doi: 10.1111/nep.13164.</citation>
    <PMID>28898482</PMID>
  </reference>
  <reference>
    <citation>Peerapornratana S, Manrique-Caballero CL, Gómez H, Kellum JA. Acute kidney injury from sepsis: current concepts, epidemiology, pathophysiology, prevention and treatment. Kidney Int. 2019 Nov;96(5):1083-1099. doi: 10.1016/j.kint.2019.05.026. Epub 2019 Jun 7. Review.</citation>
    <PMID>31443997</PMID>
  </reference>
  <reference>
    <citation>SepNet Critical Care Trials Group. Incidence of severe sepsis and septic shock in German intensive care units: the prospective, multicentre INSEP study. Intensive Care Med. 2016 Dec;42(12):1980-1989. doi: 10.1007/s00134-016-4504-3. Epub 2016 Sep 29. Erratum in: Intensive Care Med. 2017 Dec 1;:.</citation>
    <PMID>27686355</PMID>
  </reference>
  <reference>
    <citation>Fani F, Regolisti G, Delsante M, Cantaluppi V, Castellano G, Gesualdo L, Villa G, Fiaccadori E. Recent advances in the pathogenetic mechanisms of sepsis-associated acute kidney injury. J Nephrol. 2018 Jun;31(3):351-359. doi: 10.1007/s40620-017-0452-4. Epub 2017 Dec 23. Review.</citation>
    <PMID>29273917</PMID>
  </reference>
  <reference>
    <citation>Dellinger RP, Bagshaw SM, Antonelli M, Foster DM, Klein DJ, Marshall JC, Palevsky PM, Weisberg LS, Schorr CA, Trzeciak S, Walker PM; EUPHRATES Trial Investigators. Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial. JAMA. 2018 Oct 9;320(14):1455-1463. doi: 10.1001/jama.2018.14618.</citation>
    <PMID>30304428</PMID>
  </reference>
  <reference>
    <citation>Pérez-Fernández X, Sabater-Riera J, Sileanu FE, Vázquez-Reverón J, Ballús-Noguera J, Cárdenas-Campos P, Betbesé-Roig A, Kellum JA. Clinical variables associated with poor outcome from sepsis-associated acute kidney injury and the relationship with timing of initiation of renal replacement therapy. J Crit Care. 2017 Aug;40:154-160. doi: 10.1016/j.jcrc.2017.03.022. Epub 2017 Mar 30.</citation>
    <PMID>28407544</PMID>
  </reference>
  <reference>
    <citation>Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996 Jul;22(7):707-10.</citation>
    <PMID>8844239</PMID>
  </reference>
  <results_reference>
    <citation>Bouchard J, Acharya A, Cerda J, Maccariello ER, Madarasu RC, Tolwani AJ, Liang X, Fu P, Liu ZH, Mehta RL. A Prospective International Multicenter Study of AKI in the Intensive Care Unit. Clin J Am Soc Nephrol. 2015 Aug 7;10(8):1324-31. doi: 10.2215/CJN.04360514. Epub 2015 Jul 20.</citation>
    <PMID>26195505</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 27, 2019</study_first_submitted>
  <study_first_submitted_qc>August 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2019</study_first_posted>
  <last_update_submitted>March 19, 2020</last_update_submitted>
  <last_update_submitted_qc>March 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Southeast University, China</investigator_affiliation>
    <investigator_full_name>Songqiao Liu</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>Septic shock, AKI, CRRT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>there is a plan to make individual participant data (IPD) available to other researchers</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Starting 6 months after publication</ipd_time_frame>
    <ipd_access_criteria>The corresponding author will review requests form and provide the IPD</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

